NCT01832467已完成2 期
A Pilot Case-control Study of Second or Third Line Treatment With Cetuximab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer Who Were Previously Treated With Cetuximab-based Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- overall response of re-treatment with cetuximab-based chemotherapy
研究概览
简要总结
To determine the objective overall response of re-treatment with cetuximab-based chemotherapy in patients upon disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older.
- •Able to give written informed consent.
- •Histologically confirmed colorectal adenocarcinoma: must be either metastatic disease or unresectable recurrent disease.
- •KRAS mutation status of the primary or metastastic CRC tumor must be wild-type.
- •ECOG performance status of 0-1 at study entry.
- •Must have measurable disease by RECIST (ver 1.1) criteria.
- •Have progressive disease based on all of the following criteria (from a-d):
- •(a) Previously received cetuximab-based chemotherapy as first- or second-line treatment for metastatic or recurrent disease with, any one of the following drug combinations: (i) Cetuximab, fluoropyrimidines and oxaliplatin; or, (ii) Cetuximab, fluoropyrimidines and irinotecan; or (iii) Cetuximab and irinotecan. (b) Must have achieved at least stable disease, partial or complete response to treatment stated in '(a)' above.
- •(c) Experienced disease progression after more than 60 days from the last date of administration of the treatment stated in '(a)' above.
- •(d) 'Disease progression' can be defined as radiological or clinical progression.
- •Adequate hematologic, renal, hepatic function as defined by: absolute neutrophil count >= 1.5 x 109/L, hemoglobin >= 9 g/L, platelets >= 100 x 109/L, calculated creatinine clearance >=55 ml/min, total bilirubin <= 2 x the upper limit of normal (ULN), alanine aminotransferase (ALT) <2.5 upper limit of normal or <= 5 x ULN in the presence of liver metastases.
- •Must have recovered to grade 0-1 in severity, any toxicity related to previous cetuximab.
排除标准
- •Disease progression during first-line or second-line treatment with cetuximab and chemotherapy in combination.
- •Patients who had prior cetuximab in BOTH first and second-line setting.
- •Previous use of bevacizumab.
- •Prior grade 3 to 4 hypersensitivity reaction to cetuximab.
- •Clinically significant and poorly controlled medical illnesses within the last 6 months which may be exacerbated by study treatment.
- •Estimated life expectancy of less than 3 months.
- •Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before enrollment. Radiotherapy for pain relief is allowed as long as not targeted at an index or non-index lesion, e.g., bone metastases.
- •Known brain and/or leptomeningeal metastases.
- •Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias
- •Pregnancy or lactation
- •Previous malignancy other than colorectal cancer in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix. The non-CRC malignancy must be in known complete remission for at least 5 years prior to enrollment.
- •The presence of KRAS mutation in any of the CRC tumor tissue(s) - for example, patients with synchronous primary CRCs with different KRAS mutation status.
- •Participants with reproductive potential who are unwilling to perform effective contraception.
研究组 & 干预措施
cetuximab-containing chemotherapy
Experimental
- Cetuximab may be given at either one of the following schedules at the investigator's discretion:
- 2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.
- Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.
- Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.
Regimens to be combined with biweekly cetuximab:
- Irinotecan at 2-weekly schedule.
- FOLFIRI (as inpatient or via ambulatory pump).
- FOLFOX (as inpatient or via ambulatory pump).
干预措施: cetuximab-containing chemotherapy (Drug)
结局指标
主要结局
overall response of re-treatment with cetuximab-based chemotherapy
时间窗: 2 years
in patients experiencing disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.
次要结局
- progression-free survival(2 years)
- Adverst event and toxicity during treatment period(2 years)
- disease control rate(2 years)
研究者
CCTU
Comprehensive Clinical Trial Unit
Chinese University of Hong Kong
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon CancerColon CancerNCT06322147Qilu Hospital of Shandong University50
已完成
3 期
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric CancerGastric CancerNCT00678535Merck KGaA, Darmstadt, Germany904
终止
2 期
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRCColorectal CancerNCT00755534Hellenic Oncology Research Group68
终止
2 期
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without BevacizumabColorectal NeoplasmsNCT00321100Fox Chase Cancer Center23
已完成
2 期
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)Cancer of Head and NeckNCT00343083University of Maryland, Baltimore43